MK6482-033 A Phase 3, Randomized, Open-label Study of Belzutifan + Zanzalintinib Versus Cabozantinib in Participants with Advanced RCC who Experienced Disease Recurrence During or After Prior Adjuvant Anti-PD-1/L1 Therapy (LITESPARK-033)



Mary Beth Wilwerding, RN Admin@NEcancertrials.com



Available at Nebraska Cancer Specialists, Omaha and Grand Island, NE locations

Interested in More Information?

Please fill out the form below. Someone will get back to you as soon as possible.

"*" indicates required fields

Name*

Email*

Phone*

Message*